Colorectal Cancer Clinical Trials in Salt Lake City

Showing 101-120 of 145 trials

A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer

NCT03035253

The purpose of this study is to test the safety and efficacy of an experimental drug, OMP-305B83, when given in combination with FOLFIRI or FOLFOX. OMP-305B83 is a humanized bispecific monoclonal antibody and was developed to target cancer stem cells. Based on preclinical studies, it is believed that OMP-305B83 may block the growth of cancer stem cells and may also impair the productive growth of new blood vessels, which tumors need to grow and spread. The study is sponsored by OncoMed Pharmaceuticals, which is referred to as OncoMed or the Sponsor.

Metastatic Colorectal Cancer

OncoMed Pharmaceuticals, Inc.16 participantsStarted Dec 2016

Duarte, California, United States • Denver, Colorado, United States • Fort Collins, Colorado, United States +3 more locations

TERMINATED< 1 mile

Observational Study of Sub-populations From Cologuard Post-Approval Study (2014-01)

NCT03705013

The primary endpoint is to obtain longitudinal information on four sub-populations from the Cologuard Post-Approval Study.

Colorectal Cancer

Exact Sciences Corporation51 participantsStarted Oct 2018

Glendale, Arizona, United States • Mesa, Arizona, United States • Tempe, Arizona, United States +17 more locations

A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer

Observational Study of Sub-populations From Cologuard Post-Approval Study (2014-01)

Colorectal Cancer Trials in Other Cities

A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer

Study of Ruxolitinib in Colorectal Cancer Patients

A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer

A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer

A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer

Genetic Trial to Study Diarrhea in Patients With Stage III Colon Cancer Who Are Receiving Chemotherapy

Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer

Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer

Long-term Follow-up Study Designed to Evaluate the Relative Risk of Two Colonoscopy Schedules for Patients With Small Polyps

Vitamin D/Calcium Polyp Prevention Study

Screening Tests in Detecting Colorectal Cancer

PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study

Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer

Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy in Treating Patients Who Are Undergoing Surgical Resection for Locally Advanced Rectal Cancer

Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors

Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy

Paired Analysis of Sensitivity for Colorectal Cancer Using COLVERA : PASCAL

Validation of Colon Biomarkers for the Early Detection of Colorectal Adenocarcinoma

Other Conditions in Salt Lake City